Behavioral insights into adherence to pharmacotherapy for hypercholesterolemia, hypertension, and osteoporosis

American Journal of Pharmacy Benefits

Volumn 3, Issue 3, 2011, Pages

  Cadarette, Suzanne M ^a   van Wijk, Boris L G ^b   Patrick, Amanda R ^c   Brookhart, M Alan ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ARTICLE; BEHAVIOR THEORY; BONE DENSITOMETRY; CHANGE THEORY; CONTROLLED STUDY; CROSSOVER PROCEDURE; HEALTH BELIEF MODEL; HEALTH CARE UTILIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; THEORY VALIDATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84859764342     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008;26(1):145-153.
2. Fitz-Simon N, Bennett K, Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag. 2005;1(2):93-106.
3. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493-1501.
4. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023-1031.
5. Caetano PA, Lam JMC, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-1424.
6. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437-443.
7. Goldenberg N, Glueck C. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2009;5(1): 369-376.
8. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847-852.
9. van Wijk BL, Avorn J, Solomon DH, et al. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens. 2007;25(3):689-697.
10. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007;120(3): 251-256.
11. Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19(8):607-613.
12. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27(10):1639-1646.
13. Melo M, Qiu F, Sykora K, Juurlink D, Laupacis A, Mamdani M. Persistence with bisphosphonate therapy in older people. J Am Geriatr Soc. 2006;54(6): 1015-1016.
14. Urquhart J, de Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998;17(3): 251-267.
15. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
16. Glanz K, Rimer BK, Lewis FM. Health Behavior and Health Education: Theory, Research, and Practice. 3rd ed. San Francisco, CA: Jossey-Bass; 2002.
17. Elder JP, Ayala GX, Harris S. Theories and intervention approaches to healthbehavior change in primary care. Am J Prev Med. 1999;17(4):275-284.
18. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999; 47(6):555-567.
19. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521-528.
20. National Council on Patient Information and Education. Enhancing Prescription Medication Adherence: A National Action Plan. http://psnet.ahrq.gov/resource.aspx?resourceID=5937. Published August 2007. Accessed June 27, 2011.
21. Weinstein ND, Sandman PM. The precaution adoption process model. In: Glanz K, Rimer BK, Lewis FM, eds. Health Behavior and Health Education. Theory, Research, and Practice. 3rd ed. San Francisco, CA: Jossey-Bass; 2002:121-143.
22. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q. 1984;11(1):1-47.
23. Janz NK, Champion VL, Strecher VJ. The health belief model. In: Glanz K, Rimer BK, Lewis FM, eds. Health Behavior and Health Education: Theory, Research, and Practice. 3rd ed. San Francisco, CA: Jossey-Bass; 2002:45-66.
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5): 487-497.
25. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153.
26. Maclure M. 'Why me?' versus 'why now?'-differences between operational hypotheses in case-control versus case-crossover studies. Pharmacoepidemiol Drug Saf. 2007;16(8):850-853.
27. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
28. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipidlowering therapy. Am J Health Syst Pharm. 2005;62(14):1468-1475.
29. Delmas PD, Vrijens B, Eastell R, et al; Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis [published correction appears in J Clin Endocrinol Metab. 2007;92(6):2285]. J Clin Endocrinol Metab. 2007;92(4):1296-1304.
30. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117-1123.
31. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004;22(suppl 3):13-23.
32. Jaén CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of clinical preventive services. J Fam Pract. 1994;38(2): 166-171.
33. Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH. Evidence-based interventions to improve patient compliance with antihypertensive and lipidlowering medications. Int J Clin Pract. 2005;59(12):1441-1451.
34. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions. Arch Intern Med. 2007;167(6):540-550.
35. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15(10):767-778.
36. Jaglal SB, Cameron C, Hawker GA, et al. Development of an integratedcare delivery model for post-fracture care in Ontario, Canada. Osteoporos Int. 2006;17(9):1337-1345.